纳米技术在乳腺癌诊断和治疗中的研究进展_West China Medical Journal

Authors：

雷娜 ,  罗锋

Corresponding author：

罗锋, Email: leina2009@163.com

Keywords：

纳米技术; 载药系统; 乳腺癌; 主动靶向

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

近年来，纳米技术在医学领域的应用研究得到了迅速发展。在乳腺癌的诊断和治疗中，纳米技术不仅可以高效精确地定量检测肿瘤组织的分子标志物，显示微小的恶性病灶和前哨淋巴结，还可为抗肿瘤药物、放射增敏剂、基因治疗等提供良好的药物载体，显示了其广阔的应用前景。

Citation： 雷娜,罗锋. 纳米技术在乳腺癌诊断和治疗中的研究进展. West China Medical Journal, 2012, 27(5): 775-778. doi: Copy

1.	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
2.	Tanaka T, Paolo D, Cristofanilli M, et al. Nanotechnology for breast cancer therapy[J]. Biomed Microdevices, 2009, 11(1): 49-63.
3.	Kim B, Rutk JT, Chan W. Nanomedicine[J]. N Engl J Med, 2010, 363: 2434-2443.
4.	Xiao Y, Telford WG, Ball JC, et al. Semiconductor nanocrystal conjugates, FISH and pH[J]. Nat Methods, 2005, 2(10): 723.
5.	Chen C, Sun SR, Gong YP, et al. Quantum dots-based molecular classiﬁcation of breast cancer by quantitative spectroanalysis of hormone receptors and HER2[J]. Biomaterials, 2011, 32(30): 7592-7599.
6.	Yezhelyev MV, Al HA, Morris C, et al. In situ molecular profling of breast cancer biomarkers with multicolor quantum dots[J]. Adv Materials, 2007, 19(20): 3146-3151.
7.	Peters NH, Borel Rinkes IH, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions[J]. Radiology, 2008, 246(1): 116-124.
8.	陈栋, 罗阳, 黄庆, 等. 量子点及其在肿瘤诊断中的应用研究进展[J]. 国际检验医学杂志, 2011, 32(5): 589-591.
9.	Sunderland CJ, Steiert M, Talmadge JE, et al. Nanoparticles for detecting and treating cancer[J]. Drug Dev Res, 2006, 67(1): 70-93.
10.	刘国华, 陈燕明. 超微超顺磁性氧化铁纳米粒及其在肿瘤磁共振成像中的应用[J]. 医学综述, 2010, 16(16): 2494-2497.
11.	李绪斌, 杜湘珂, 霍天龙, 等. 乳腺癌特异性磁共振分子探针的制备及体外实验[J]. 北京大学学报:医学版, 2009, 41(2): 179-183.
12.	Meng J, Fan J, Galiana G, et al. LHRH-functionalized superparamagnetic Iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI[J]. Mater Sci Eng, 2009, 29(4): 1467-1479.
13.	Uren RF. Cancer surgery joins the dots[J]. Nat Biotechnol, 2004, 22(1): 38-39.
14.	Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent typeⅡquantum dots for sentinel lymph node mapping[J]. Nat Biotechnol, 2004, 22(1): 93-97.
15.	Hyun SK, Kim C, Maslov K, et al. Noninvasive in vivo spectroscopic nanorod-contrast photoacoustic mapping of sentinel lymph nodes[J]. Eur J Radiol, 2009, 70(2): 227-231.
16.	Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications[J]. Int Immunopharmacol, 2003, 3(3): 319-328.
17.	贾晋斌, 韦青燕. 阿霉素脂质体的研究进展[J]. 中国肿瘤, 2011, 20(5): 372-377.
18.	Chan S, Davidson N, Juozaityte E, et al. PhaseⅢ trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer[J]. Ann Oncol, 2004, 15(10): 1527-1534.
19.	O’brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phaseⅢ trial of pegylated liposomal doxorubicin HCL(Caelyxtm/Doxil®)versus conventional doxorubicin for ﬁrst-line treatment of metastatic breast cancer[J]. Ann Oncol, 2004, 15(3): 440-449.
20.	尹晓东, 姚嫱, 李维廉. 白蛋白结合型紫杉醇的研究进展[J]. 现代肿瘤医学, 2011, 19(7): 1449-1452.
21.	王莉, 王季堃, 李巍, 等. p53对MDR1在肿瘤中表达的影响及研究进展[J]. 中国医学工程, 2010, 18(4): 161-162.
22.	Onyüksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells[J]. Cancer Lett, 2009, 274(2): 327-330.
23.	Shuhendler AJ, Cheung RY, Manias J, et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells[J]. Breast Cancer Res Treat, 2010, 119(2): 255-269.
24.	Patil YB, Swaminathan SK, Sanhukha T, et al. The use of nanoparticle-mediated targeted gene silence and drug delivery to overcome tumor drug resistance[J]. Biomaterials, 2010, 31 (2): 358-365.
25.	Cho S, Jeong JH, Kim CH, et al. Monte Carlo simulation study on dose enhancement by Gold nanoparticles in brachytherapy[J]. J Korean Astron Soc, 2010, 56(6): 1754-1758.
26.	Nath R, Yue N, Weinberger J. Dose perturbations by high atomic number materials in intravascular brachytherapy[J]. Cardiovasc Radiat Med, 1999, 1(2): 144-153.
27.	Khafif A, Hurst R, Kyker K, et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells[J]. Otolaryngol Head Neck Surg, 2005, 132(2): 317-321.
28.	Chang MY, Shiau AL, Chen YH, et al. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice[J]. Cancer Sci, 2008, 99(7): 1479-1484.
29.	Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization[J]. J Control Release, 2009, 139(3): 239-245.
30.	Takahashi S, Ito Y, Hatake K, et al. Gene therapy for breast cancer. Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital[J]. Breast Cancer, 2006, 13(1): 8-15.
31.	刘晓华, 税青林. 乳腺癌的基因治疗研究[J]. 现代诊断与治疗, 2011, 22(1): 29-31.
32.	Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges[J]. Prog Mol Biol Transl Sci, 2011, 104: 509-562.
33.	Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells[J]. Mol Pharm, 2004, 1(3): 211-219.
34.	Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products[J]. Oncogene, 1991, 6(2): 343-345.
35.	Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer[J]. Int J Pharm, 2005, 293(1-2): 261-270.
36.	Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance[J]. Proc Natl Acad Sci USA, 2003, 100(23): 13549-13554.
37.	Shubayev VI, Pisanic IR, Jin S. Magnetic nanoparticles for theragnostics[J]. Adv Drug Deliv Rev, 2009, 61(6): 467-477.
38.	Lukianova-Hleb EY, Hanna EY, Hafner JH, et al. Tunable plasmonic nanobubbles for cell theranostics[J]. Nanotechnology, 2010, 21(8): 85102.
39.	Suk SM, Soo KC, Yeh-Chan A, et al. Combined multimodal optical imaging and targeted gene silencing using stimuli-transforming nanotheragnostics[J]. J Am Chem Soc, 2010, 132(24): 8316-8324.
40.	Loo C, Lowery A, Halas N, et al. Immunotargeted nanoshells for integrated cancer imaging and therapy[J]. Nano Lett, 2005, 5(4): 709-711.
41.	Rastogi A. Nanooncology: the breast cancer story[J]. UTMJ, 2011, 88(3): 190-194.

1. 　Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
2. 　Tanaka T, Paolo D, Cristofanilli M, et al. Nanotechnology for breast cancer therapy[J]. Biomed Microdevices, 2009, 11(1): 49-63.
3. 　Kim B, Rutk JT, Chan W. Nanomedicine[J]. N Engl J Med, 2010, 363: 2434-2443.
4. 　Xiao Y, Telford WG, Ball JC, et al. Semiconductor nanocrystal conjugates, FISH and pH[J]. Nat Methods, 2005, 2(10): 723.
5. 　Chen C, Sun SR, Gong YP, et al. Quantum dots-based molecular classiﬁcation of breast cancer by quantitative spectroanalysis of hormone receptors and HER2[J]. Biomaterials, 2011, 32(30): 7592-7599.
6. 　Yezhelyev MV, Al HA, Morris C, et al. In situ molecular profling of breast cancer biomarkers with multicolor quantum dots[J]. Adv Materials, 2007, 19(20): 3146-3151.
7. 　Peters NH, Borel Rinkes IH, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions[J]. Radiology, 2008, 246(1): 116-124.
8. 　陈栋, 罗阳, 黄庆, 等. 量子点及其在肿瘤诊断中的应用研究进展[J]. 国际检验医学杂志, 2011, 32(5): 589-591.
9. 　Sunderland CJ, Steiert M, Talmadge JE, et al. Nanoparticles for detecting and treating cancer[J]. Drug Dev Res, 2006, 67(1): 70-93.
10. 　刘国华, 陈燕明. 超微超顺磁性氧化铁纳米粒及其在肿瘤磁共振成像中的应用[J]. 医学综述, 2010, 16(16): 2494-2497.
11. 　李绪斌, 杜湘珂, 霍天龙, 等. 乳腺癌特异性磁共振分子探针的制备及体外实验[J]. 北京大学学报:医学版, 2009, 41(2): 179-183.
12. 　Meng J, Fan J, Galiana G, et al. LHRH-functionalized superparamagnetic Iron oxide nanoparticles for breast cancer targeting and contrast enhancement in MRI[J]. Mater Sci Eng, 2009, 29(4): 1467-1479.
13. 　Uren RF. Cancer surgery joins the dots[J]. Nat Biotechnol, 2004, 22(1): 38-39.
14. 　Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent typeⅡquantum dots for sentinel lymph node mapping[J]. Nat Biotechnol, 2004, 22(1): 93-97.
15. 　Hyun SK, Kim C, Maslov K, et al. Noninvasive in vivo spectroscopic nanorod-contrast photoacoustic mapping of sentinel lymph nodes[J]. Eur J Radiol, 2009, 70(2): 227-231.
16. 　Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications[J]. Int Immunopharmacol, 2003, 3(3): 319-328.
17. 　贾晋斌, 韦青燕. 阿霉素脂质体的研究进展[J]. 中国肿瘤, 2011, 20(5): 372-377.
18. 　Chan S, Davidson N, Juozaityte E, et al. PhaseⅢ trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer[J]. Ann Oncol, 2004, 15(10): 1527-1534.
19. 　O’brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phaseⅢ trial of pegylated liposomal doxorubicin HCL(Caelyxtm/Doxil®)versus conventional doxorubicin for ﬁrst-line treatment of metastatic breast cancer[J]. Ann Oncol, 2004, 15(3): 440-449.
20. 　尹晓东, 姚嫱, 李维廉. 白蛋白结合型紫杉醇的研究进展[J]. 现代肿瘤医学, 2011, 19(7): 1449-1452.
21. 　王莉, 王季堃, 李巍, 等. p53对MDR1在肿瘤中表达的影响及研究进展[J]. 中国医学工程, 2010, 18(4): 161-162.
22. 　Onyüksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells[J]. Cancer Lett, 2009, 274(2): 327-330.
23. 　Shuhendler AJ, Cheung RY, Manias J, et al. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells[J]. Breast Cancer Res Treat, 2010, 119(2): 255-269.
24. 　Patil YB, Swaminathan SK, Sanhukha T, et al. The use of nanoparticle-mediated targeted gene silence and drug delivery to overcome tumor drug resistance[J]. Biomaterials, 2010, 31 (2): 358-365.
25. 　Cho S, Jeong JH, Kim CH, et al. Monte Carlo simulation study on dose enhancement by Gold nanoparticles in brachytherapy[J]. J Korean Astron Soc, 2010, 56(6): 1754-1758.
26. 　Nath R, Yue N, Weinberger J. Dose perturbations by high atomic number materials in intravascular brachytherapy[J]. Cardiovasc Radiat Med, 1999, 1(2): 144-153.
27. 　Khafif A, Hurst R, Kyker K, et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells[J]. Otolaryngol Head Neck Surg, 2005, 132(2): 317-321.
28. 　Chang MY, Shiau AL, Chen YH, et al. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice[J]. Cancer Sci, 2008, 99(7): 1479-1484.
29. 　Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization[J]. J Control Release, 2009, 139(3): 239-245.
30. 　Takahashi S, Ito Y, Hatake K, et al. Gene therapy for breast cancer. Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital[J]. Breast Cancer, 2006, 13(1): 8-15.
31. 　刘晓华, 税青林. 乳腺癌的基因治疗研究[J]. 现代诊断与治疗, 2011, 22(1): 29-31.
32. 　Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges[J]. Prog Mol Biol Transl Sci, 2011, 104: 509-562.
33. 　Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells[J]. Mol Pharm, 2004, 1(3): 211-219.
34. 　Yan DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products[J]. Oncogene, 1991, 6(2): 343-345.
35. 　Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer[J]. Int J Pharm, 2005, 293(1-2): 261-270.
36. 　Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance[J]. Proc Natl Acad Sci USA, 2003, 100(23): 13549-13554.
37. 　Shubayev VI, Pisanic IR, Jin S. Magnetic nanoparticles for theragnostics[J]. Adv Drug Deliv Rev, 2009, 61(6): 467-477.
38. 　Lukianova-Hleb EY, Hanna EY, Hafner JH, et al. Tunable plasmonic nanobubbles for cell theranostics[J]. Nanotechnology, 2010, 21(8): 85102.
39. 　Suk SM, Soo KC, Yeh-Chan A, et al. Combined multimodal optical imaging and targeted gene silencing using stimuli-transforming nanotheragnostics[J]. J Am Chem Soc, 2010, 132(24): 8316-8324.
40. 　Loo C, Lowery A, Halas N, et al. Immunotargeted nanoshells for integrated cancer imaging and therapy[J]. Nano Lett, 2005, 5(4): 709-711.
41. 　Rastogi A. Nanooncology: the breast cancer story[J]. UTMJ, 2011, 88(3): 190-194.

West China Medical Journal

纳米技术在乳腺癌诊断和治疗中的研究进展

Abstract Full text Figures/Tables Video References Cited by

Format

Content